Uremic neuropathy: evidence of middle molecule toxicity

Evidence for a causal relationship between hyperkalaemia and axonal dysfunction in end-stage kidney disease

OBJECTIVE

Potassium (K(+)) has been implicated as a factor in the development of uraemic neuropathy. This study was undertaken to investigate whether hyperkalaemia plays a causal role in axonal dysfunction in end-stage kidney disease (ESKD).

METHODS

Median motor nerve excitability studies were undertaken in four haemodialysis patients during a modified dialysis session. The serum K(+) level was "clamped" (fixed) for the first 3h of dialysis, whilst allowing all other solutes to be removed, this was followed by dialysis against low dialysate K(+) for a further 4 h. Blood chemistry and nerve excitability studies were undertaken prior to, during and following dialysis. Results were compared to results from the same patients during routine dialysis sessions.

RESULTS

All patients demonstrated significant nerve excitability abnormalities reflective of nerve membrane depolarization in pre-dialysis recordings (p<0.01). After the 3 h clamp period, serum K(+) remained elevated (5.0 mmol/L) and nerve excitability remained highly abnormal, despite the significant clearance of other uraemic toxins. In contrast, studies undertaken during routine dialysis sessions demonstrated significant improvement in both serum K(+) and nerve function after 3 h.

CONCLUSIONS

The current study has established a causal relationship between serum K(+) and axonal membrane depolarization in haemodialysis patients.

SIGNIFICANCE

From a clinical perspective, strict K(+) control may help improve nerve function in ESKD.

Review Article: is it time to embrace haemodiafiltration for centre-based haemodialysis?

Improvements in survival in dialysis patients over the past few decades have been disappointing. Recent prospective trials such the haemodialysis study have not shown conclusive improvements. Two recent observational studies have found a striking survival advantage for haemodiafiltration (HDF). This review covers the differences between HDF and conventional haemodialysis (HD) and the history of the technological advances in the HDF technique. In addition, it explores the putative benefits of HDF over HD. While the observational studies provide a basis for optimism that HDF will provide benefit to dialysis patients, definitive conclusions cannot be drawn until the results of randomized controlled trials are available. While the evidence in favour of HDF at this stage is observational only, there are no studies suggesting that the treatment is detrimental. The use of HDF should probably be increased, particularly in centres where an increase in the frequency and duration of dialysis cannot be readily achieved.

Residual renal function in hemodialysis patients may protect against hyperaluminemia

We investigated 106 home hemodialysis patients whose mean [+/- SEM] serum aluminum (Al) concentration was 60.9 +/- 4.1 micrograms/liter. Serum Al concentration was inversely related to daily urine output (r = -0.52, P less than 0.001). Urine volume and measurements of Al exposure were included in a multivariate analysis of serum Al concentration in the 62 patients whose urine output was greater than 10 ml/day. The multiple correlation coefficient (r) was 0.70 (P less than 0.001) and the percentage contributions to r2 (indicating the relative importance of each factor) were: urine output 57%, oral Al intake 36%, total dialysis hours 7%. The additional contribution from cumulative water Al was negligible. In a subgroup of 26 patients with a urine output exceeding 10 ml/day, urinary Al excretion averaged 15.4 micrograms/day, and renal Al clearance and serum Al concentration were inversely related (r = -0.69, P less than 0.001). We conclude that Al-containing phosphate binders were a more important source of Al than was dialysate in these patients and that residual renal function can reduce the severity of hyperaluminemia in hemodialysis patients.

The middle molecule hypothesis in perspective

The middle molecule (MM) hypothesis states that molecules in the molecular weight range of 500 to 2000 daltons/molecule accumulate in uremia and are one cause of peripheral neuropathy. Evidence for and against this hypothesis is reviewed and evaluated. The course of events in the core of early hemodialysis patients who developed neuropathy provides important support ofr the hypothesis. Failure of early peritoneal dialysis patients to develop neuropathy suggested that the peritoneum is more permeable to MM's than early hemodialysis membranes, a fact that was later hemodialysis membranes, a fact that was later confirmed by appropriate investigations. Several investigators have demonstrated that MM's actually do accumulate in uremia and disappear rapidly following a renal transplant, which suggests a high clearance by the human kidney. Retrospective and prospective studies have demonstrated a protective effect of residual renal function against MM intoxication. Our prospective studies to produce MM intoxication are reviewed and their strengths and weaknesses delineated. Similarly, the investigations of others that are cited as evidence against the MM hypothesis are reviewed. It is the opinion of hte authors that the weight of evidence supports the validity of the MM hypothesis; but that final proof still is lacking. A protocol for more definitive studies is discussed.